Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: Markers of response to GMA

BMC Gastroenterology

Volumn 13, Issue 1, 2013, Pages

  Yokoyama, Yoko ^a   Kawai, Mikio ^a   Fukunaga, Ken ^a   Kamikozuru, Koji ^a   Nagase, Kazuko ^a   Nogami, Koji ^a   Kono, Tomoaki ^a   Ohda, Yoshio ^a   Iimuro, Masaki ^a   Hida, Nobuyuki ^a   Nakamura, Shiro ^a   Miwa, Hiroto ^a   Matsumoto, Takayuki ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Duration of ulcerative colitis; Granulocyte and monocyte adsorptive apheresis; Multiple logistic regression analysis; Predictive factors of clinical response; Receiver operating characteristic; Ulcerative colitis; Univariate analyses

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; AZATHIOPRINE; PREDNISOLONE; STEROID;

ADSORPTIVE GRANULOCYTE AND MONOCYTE APHERESIS; ADULT; AGED; APHERESIS; ARTICLE; CLINICAL ARTICLE; DISEASE DURATION; FEMALE; GRANULOCYTE; HUMAN; HUMAN CELL; JAPAN; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; MONOCYTE; MORBIDITY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREDICTION; RECEIVER OPERATING CHARACTERISTIC; RELAPSE; REMISSION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; C-REACTIVE PROTEIN; COLITIS, ULCERATIVE; FEMALE; GRANULOCYTES; HEMOGLOBINS; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MONOCYTES; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873699322     PISSN: None     EISSN: 1471230X     Source Type: Journal    
DOI: 10.1186/1471-230X-13-27     Document Type: Article

References (38)

1. Allison MC, Dhillon AP, Lewis WG, Pounder RE. Inflammatory Bowel Disease 1998, 9-95. London: Mosby.
2. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002, 347:417-419. 10.1056/NEJMra020831, 12167685.
3. Mizoguchi A, Mizoguchi E. Inflammatory bowel disease, past, present and the future: lessons from animal models. Gastroenterology 2008, 43:1-17.
4. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434. 10.1038/nature06005, 17653185.
5. Yokoyama Y, Fukunaga K, Fukuda Y, Tozawa K, Kamikozuru K, Ohnishi K, Kusaka T, Kosaka T, Hida N, Ohda Y, Miwa H, Matsumoto T. Demonstration of low-regulatory CD25HighCD4+ and high-pro-inflammatory CD28-CD4+ T-Cell subsets in patients with ulcerative colitis: modified by selective granulocyte and monocyte adsorption apheresis. Dig Dis Sci 2007, 52:2725-2731. 10.1007/s10620-006-9560-z, 17404876.
6. Saniabadi AR, Hanai H, Fukunaga K, Sawada K, Shima C, Bjarnason I, Lofberg R. Therapeutic Leucocytapheresis for inflammatory bowel disease. Transf Aphere Sci 2007, 37:191-200.
7. Hanai H, Takeda Y, Eberhardson M, Gruber R, Saniabadi AR, Winqvist O, Lofberg. The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review. Clin Exp Immunol 2011, 163:50-58. 10.1111/j.1365-2249.2010.04279.x, 3010911, 21078086.
8. Sakuraba A, Motoya S, Watanabe K, Nishishita M, Kanke K, Matsui T, Suzuki Y, Oshima T, Kunisaki R, Matsumoto T, Hanai H, Fukunaga K, Yoshimura N, Chiba T, Funakoshi S, Aoyama N, Andoh A, Nakase H, Mizuta Y, Suzuki R, Akamatsu T, Iizuka M, Ashida T, Hibi T. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol 2009, 104:2990-2995. 10.1038/ajg.2009.453, 19724269.
9. Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective granulocyte and monocyte adsorptive apheresis as a first-line treatment for steroid naïve patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci 2004, 49:565-571.
10. Domenech E, Hinojosa J, Esteve-Comas M, . Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU) Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther 2004, 20:1347-1352. 10.1111/j.1365-2036.2004.02288.x, 15606397, Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU).
11. Caprilli R, D'Ovidio V. Leukocytapheresis as promising therapy for inflammatory bowel disease. Dig Liver Dis 2007, 39:435-437. 10.1016/j.dld.2007.02.003, 17379590.
12. Cohen RD. Treating ulcerative colitis without medications - " Look Mom, No Drugs!" . Gastroenterology 2005, 128:235-236. 10.1053/j.gastro.2004.11.024, 15633142.
13. Hanai H, Watanabe F, Takeuchi K, Iida T, Yamada M, Iwaoka Y, Saniabadi A, Matsushita I, Sato Y, Tozawa K, Arai H, Furuta T, Sugimoto K, Bjarnason I. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003, 1:28-35. 10.1053/jcgh.2003.50005, 15017514.
14. Hibi T, Sameshima Y, Sekiguchi Y, Hisatome Y, Maruyama F, Moriwaki K, Shima C, Saniabadi AR, Matsumoto T. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis 2009, 41:570-577. 10.1016/j.dld.2008.11.020, 19211314.
15. Sands BE, Sandborn WJ, Feagan B, Löfberg R, Hibi T, Wang T, Gustofson LM, Wong CJ, Vandrvoot MK, Hanauer S. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology 2008, 135:400-409. 10.1053/j.gastro.2008.04.023, 18602921.
16. Tanaka T, Okanobu H, Kuga Y, Yoshifuku Y, Fujino H, Miwata T, Moriya T, Nishida T, Oya T. Clinical and endoscopic features of responders and non-responders to adsorptive leucocytapheresis: a report based on 120 patients with active ulcerative colitis. Gastroenterol Clin Biol 2010, 34:687-695. 10.1016/j.gcb.2010.08.007, 20934287.
17. Tanaka T, Saniabadi AR, Suzuki Y. The diagnostic value of colonoscopy in understanding inflammatory mucosal damage in patients with ulcerative colitis and predicting clinical response to adsorptive leucocytapheresis as a non-pharmacologic treatment intervention. Endoscopic Procedures in Colon and Rectum 2011, 82-94. da Rocha JJR, http://www.intechopen.com/articles/show/title/the-diagnostic-value-of-colonoscopy-in-understanding-inflammatory-mucosal-damage-in-patients-with-ul ISBN 978-953-307-677-5, InTech.
18. Cottone M, Pietrosi G, Martorana G. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 2001, 96:773-775. 10.1111/j.1572-0241.2001.03620.x, 11280549.
19. Yoshimura N, Tadami T, Kawaguchi T, Sako M, Yoshimoto H, Yamaka T, Takazoe M. Processed blood volume impacts clinical efficacy in patients with ulcerative colitis undergoing adsorptive depletion of myeloid lineage leucocytes. J Gastroenterol 2012, 47:49-55. 10.1007/s00535-011-0464-0, 21915624.
20. Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006, 55:1255-1262. 10.1136/gut.2005.081794, 1860021, 16484504.
21. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841-1845. 10.1056/NEJM199406303302601, 8196726.
22. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med 1989, 14(298):82-6.
23. Saniabadi AR, Hanai H, Takeuchi K, Umemura K, Nakashima M, Adachi T, Shima C, Bjarnason I, Lofberg R. Adacolumn, an adsorptive carrier based granulocyte and monocyte apheresis device for the treatment of inflammatory and refractory disease associated with leukocytes. Ther Apher Dial 2003, 7:48-59. 10.1046/j.1526-0968.2003.00012.x, 12921115.
24. Naganuma M, Funakoshi S, Sakuraba A, Takagi H, Inoue N, Ogata H, Iwao Y, Ishi H, Hibi T. Granulocytetapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis 2004, 10:251-257. 10.1097/00054725-200405000-00012, 15290920.
25. Tanaka T, Okanobu H, Yoshimi S, Murakami E, Kogame A, Imagawa H, Numata Y, Kuga Y, Moriya T, Ohya T, Kajiyama G. Adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients. Dig Liver Dis 2008, 40:731-736. 10.1016/j.dld.2008.02.012, 18387860.
26. Saniabadi AR, Hanai H. Therapeutic apheresis from the early civilizations to the twenty-first century. Gastroenterol Clin Biol 2010, 34:645-648. 10.1016/j.gcb.2010.09.003, 20971590.
27. Suzuki Y, Yoshimura N, Fukuda K, Shirai K, Saito Y, Saniabadi AR. A retrospective search for predictors of clinical response to selective granulocyte and monocyte apheresis in patients with ulcerative colitis. Dig Dis Sci 2006, 51:2031-2038. 10.1007/s10620-006-9199-9, 17004123.
28. Hanauer SB, Sandborn WJ, Kornbluth A, Katz S, Safdi M, Woogen S, Regalli G, Yeh C, Smith HN, Ajayi F. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: The ASCEND II Trial. Am J Gastroenterol 2005, 10:2479-85.
29. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476. 10.1056/NEJMoa050516, 16339095.
30. Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis 2010, 16:1905-1911. 10.1002/ibd.21260, 20310015.
31. Shimoyama T, Sawada K, Hiwatashi N, Sawada T, Matsueda K, Munakata A, Asakura H, Tanaka T, Kasukawa R, Kimura K, Suzuki Y, Nagamachi Y, Muto T, Nagawa H, Iizuka B, Baba S, Nasu M, Kataoka T, Kashiwagi N, Saniabadi AR. Safety and efficacy of granulocytes and monocyte adsorption apheresis in patients with active ulcerative colitis: a multiple study. J Clin Apher 2001, 16:1-9. 10.1002/jca.1000, 11309823.
32. Muratov V, Lundahl J, Ulfgren AK, Elvin K, Fehrman I, Ahlborg N, Öst A, Hittel N, Saniabadi AR, Löfberg R. Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study. Int J Colorectal Dis 2006, 21:493-504. 10.1007/s00384-005-0069-2, 16538495.
33. Ruuska T, Wewer V, Lindgren F, Malmborg P, Lindquist M, Marthinsen L, Browaldh L, Casswall T, Kalliomaki M, Gronlund J. Granulocyte-monocyte adsorptive apheresis in pediatric inflammatory bowel disease; results, practical issue, safety, and future perspectives. Inflamm Bowel Dis 2009, 15:1049-1054. 10.1002/ibd.20859, 19137602.
34. Takayama T, Kanai T, Matsuoka K, Okamoto S, Sujino T, Mikami Y, Hisamatsu T, Yamaji T, Iwao Y, Ogata H, Hibi T. Long-term prognosis of patients with ulcerative colitis treated with cytapheresis therapy. J Crohn's Colitis 2012, 7:e49-54. in press.
35. Yamamoto T, Umegae S, Matsumoto K. Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis. J Crohn's Colitis 2012, 6:750-755. 10.1016/j.crohns.2011.12.009, 22935432.
36. Kato S, Hosomi E, Amano F, Kobayashi T, Kani K, Yamamoto R, Ogata T, Matsda A, Sato Y, Izaki S, Mitarai T, Yakabi K. The efficacy of intensive granulocyte and monocyte adsorption apheresis in a patient with Crohn's disease complicated by extensive subcutaneous aseptic neutrophilic abscesses. J Crohns Colitis 2012, 6:787-791. 10.1016/j.crohns.2012.02.005, 22386738.
37. Yamamoto T, Saniabadi AR, Maruyama Y, Umegae S, Matsumoto K. Factors affecting clinical and endoscopic efficacies of selective leucocytapheresis for ulcerative colitis. Dig Liver Dis 2007, 39:626-633. 10.1016/j.dld.2007.04.007, 17532273.
38. Lindberg A, Eberhardson M, Karlsson M, Karlen P. Long-term follow-up with granulocyte and monocyte apheresis re-treatment in patients with chronically active inflammatory bowel disease. BMC Gastroenterology 2010, 10:73. 10.1186/1471-230X-10-73, 2914086, 20604939.